Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: An open-label phase I trial Journal Article
| Authors: | Meric-Bernsta, F.; Tannir, N. M.; Iliopoulos, O.; Lee, R. J.; Telli, M. L.; Fan, A. C.; DeMichele, A.; Haas, N. B.; Patel, M. R.; Harding, J. J.; Voss, M. H.; Owonikoko, T. K.; Carthon, B.; Srinivasan, R.; Bendell, J. C.; Jenkins, Y.; Whiting, S. H.; Orford, K.; Bennett, M. K.; Bauer, T. M. |
| Article Title: | Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: An open-label phase I trial |
| Abstract: | Purpose: Dual inhibition of glucose and glutamine metabolism results in synergistic anticancer effects in solid tumor models. Telaglenastat, an investigational, small-molecule, glutaminase inhibitor, exhibits modest single-agent activity in renal cell carcinoma (RCC) patients. This phase Ib trial evaluated telaglenastat plus cabozantinib or everolimus, agents known to impair glucose metabolism in patients with metastatic RCC (mRCC). Patients and Methods: mRCC patients received escalating doses of telaglenastat [400-800 mg per os (p.o.) twice daily] in a 3 + 3 design, plus either everolimus (10 mg daily p.o.; TelaE) or cabozantinib (60 mg daily p.o.; TelaC). Tumor response (RECISTv1.1) was assessed every 8 weeks. Endpoints included safety (primary) and antitumor activity. Results: Twenty-seven patients received TelaE, 13 received TelaC, with median 2 and 3 prior therapies, respectively. Treatment-related adverse events were mostly grades 1 to 2, most common including decreased appetite, anemia, elevated transaminases, and diarrhea with TelaE, and diarrhea, decreased appetite, elevated transaminases, and fatigue with TelaC. One dose-limiting toxicity occurred per cohort: grade 3 pruritic rash with TelaE and thrombocytopenia with TelaC. No maximum tolerated dose (MTD) was reached for either combination, leading to a recommended phase II dose of 800-mg telaglenastat twice daily with standard doses of E or C. TelaE disease control rate (DCR; response rate + stable disease) was 95.2% [20/21, including 1 partial response (PR)] among 21 patients with clear cell histology and 66.7% (2/3) for papillary. TelaC DCR was 100% (12/12) for both histologies [5/10 PRs as best response (3 confirmed) in clear cell]. Conclusions: TelaE and TelaC showed encouraging clinical activity and tolerability in heavily pretreated mRCC patients. © 2022 American Association for Cancer Research Inc.. All rights reserved. |
| Keywords: | clinical trial; diarrhea; pyridines; antineoplastic agent; metabolism; antineoplastic combined chemotherapy protocols; pathology; enzyme inhibitor; renal cell carcinoma; kidney neoplasms; kidney tumor; carcinoma, renal cell; enzyme inhibitors; phase 1 clinical trial; aminotransferase; everolimus; anilides; pyridine derivative; anilide; cabozantinib; transaminases; humans; human; male; female |
| Journal Title: | Clinical Cancer Research |
| Volume: | 28 |
| Issue: | 8 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-04-15 |
| Start Page: | 1540 |
| End Page: | 1548 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-21-2972 |
| PUBMED: | 35140121 |
| PROVIDER: | scopus |
| PMCID: | PMC9164172 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 May 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work